Overview

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Risperidone